Current Management in Retinoblastoma

  • Shweta Gupta
  • Swathi Kaliki
Part of the Current Practices in Ophthalmology book series (CUPROP)


Retinoblastoma is a complex eye tumor manifesting in children below the age of 3 years. Over the years, the management of retinoblastoma has undergone drastic changes, thus improving the outcomes. The primary goal of management of retinoblastoma is life salvage, and secondary and tertiary goals include globe salvage and vision salvage, respectively, and thus improvement of the quality of life of the child. The choice of treatment of retinoblastoma depends on multiple factors including patients’ age, general condition, family desires, tumor laterality, tumor classification, tumor location, associated ocular features, radiological findings, and patient compliance to treatment. Smaller tumors can be managed with focal treatment like transpupillary thermotherapy or cryotherapy, while larger tumors need intravenous chemotherapy or intra-arterial chemotherapy. Enucleation is needed in very advanced tumors. External beam radiotherapy is rarely used except in cases with extraocular extension of retinoblastoma. Other supplemental treatments with subtenon’s chemotherapy, intravitreal chemotherapy, and plaque radiotherapy improve the outcomes further.


Eye Retina Retinoblastoma Transpupillary therapy Cryotherapy Chemotherapy Radiotherapy 


  1. 1.
    Shields JA, Shields CL. Intraocular tumors: a text and atlas. Philadelphia: WB Saunders; 1992.Google Scholar
  2. 2.
    Epstein JA, Shields CL, Shields JA. Trends in the management of retinoblastoma: evaluation of 1,196 consecutive eyes during 1974 to 2001. J Pediatr Ophthalmol Strabismus. 2003;40(4):196–203.PubMedCrossRefGoogle Scholar
  3. 3.
    Shields CL, Shields JA. Retinoblastoma management: advances in enucleation, intravenous chemoreduction, and intra-arterial chemotherapy. Curr Opin Ophthalmol. 2010;21(3):203–12.PubMedCrossRefGoogle Scholar
  4. 4.
    Linn MA. Intraocular retinoblastoma: the case for a new group classification. Ophthalmol Clin N Am. 2005;18(1):41–53. viii.CrossRefGoogle Scholar
  5. 5.
    Shields CL, Mashayekhi A, Au AK, Czyz C, Leahey A, Meadows AT, et al. The international classification of retinoblastoma predicts chemoreduction success. Ophthalmology. 2006;113(12):2276–80.PubMedCrossRefGoogle Scholar
  6. 6.
    Kaliki S, Shields CL, Rojanaporn D, Al-Dahmash S, McLaughlin JP, Shields JA, et al. High-risk retinoblastoma based on international classification of retinoblastoma: analysis of 519 enucleated eyes. Ophthalmology. 2013;120(5):997–1003.PubMedCrossRefGoogle Scholar
  7. 7.
    Chantada G, Doz F, Antoneli CBG, Grundy R, Clare Stannard FF, Dunkel IJ, et al. A proposal for an international retinoblastoma staging system. Pediatr Blood Cancer. 2006;47(6):801–5.PubMedCrossRefGoogle Scholar
  8. 8.
    Bakhshi S, Meel R, Kashyap S, Sharma S. Bone marrow aspirations and lumbar punctures in retinoblastoma at diagnosis: correlation with IRSS staging. J Pediatr Hematol Oncol. 2011;33(5):e182–5.PubMedCrossRefGoogle Scholar
  9. 9.
    Honavar SG, Singh AD. Management of advanced retinoblastoma. Ophthalmol Clin. 2005;18(1):65–73.Google Scholar
  10. 10.
    Chawla B, Jain A, Azad R. Conservative treatment modalities in retinoblastoma. Indian J Ophthalmol. 2013;61(9):479–85.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Shields CL, Shields JA, Needle M, de Potter P, Kheterpal S, Hamada A, et al. Combined chemoreduction and adjuvant treatment for intraocular retinoblastoma. Ophthalmology. 1997;104(12):2101–11.PubMedCrossRefGoogle Scholar
  12. 12.
    Shields CL, Fulco EM, Arias JD, Alarcon C, Pellegrini M, Rishi P, et al. Retinoblastoma frontiers with intravenous, intra-arterial, periocular, and intravitreal chemotherapy [Internet]. Eye. 2012. Accessed 15 Nov 2017.
  13. 13.
    Shields CL, Honavar SG, Meadows AT, Shields JA, Demirci H, Singh A, et al. Chemoreduction plus focal therapy for retinoblastoma: factors predictive of need for treatment with external beam radiotherapy or enucleation. Am J Ophthalmol. 2002;133(5):657–64.PubMedCrossRefGoogle Scholar
  14. 14.
    Shields CL, De Potter P, Himelstein BP, Shields JA, Meadows AT, Maris JM. Chemoreduction in the initial management of intraocular retinoblastoma. Arch Ophthalmol. 1996;114(11):1330–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Wilson MW, Rodriguez-Galindo C, Haik BG, Moshfeghi DM, Merchant TE, Pratt CB. Multiagent chemotherapy as neoadjuvant treatment for multifocal intraocular retinoblastoma. Ophthalmology. 2001;108(11):2106–14. discussion 2114-2115.PubMedCrossRefGoogle Scholar
  16. 16.
    Shields CL, Honavar SG, Shields JA, Demirci H, Meadows AT, Naduvilath TJ. Factors predictive of recurrence of retinal tumors, vitreous seeds, and subretinal seeds following chemoreduction for retinoblastoma. Arch Ophthalmol. 2002;120(4):460–4.PubMedCrossRefGoogle Scholar
  17. 17.
    Shields CL, Mashayekhi A, Cater J, Shelil A, Meadows AT, Shields JA. Chemoreduction for retinoblastoma. Analysis of tumor control and risks for recurrence in 457 tumors. Am J Ophthalmol. 2004;138(3):329–37.PubMedCrossRefGoogle Scholar
  18. 18.
    Dunkel IJ, Jubran RF, Gururangan S, Chantada GL, Finlay JL, Goldman S, et al. Trilateral retinoblastoma: potentially curable with intensive chemotherapy. Pediatr Blood Cancer. 2010;54(3):384–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Shields CL, Ramasubramanian A, Thangappan A, Hartzell K, Leahey A, Meadows AT, et al. Chemoreduction for group E retinoblastoma: comparison of chemoreduction alone versus chemoreduction plus low-dose external radiotherapy in 76 eyes. Ophthalmology. 2009;116(3):544–551.e1.PubMedCrossRefGoogle Scholar
  20. 20.
    Kingston JE, Hungerford JL, Madreperla SA, Plowman PN. Results of combined chemotherapy and radiotherapy for advanced intraocular retinoblastoma. Arch Ophthalmol. 1996;114(11):1339–43.PubMedCrossRefGoogle Scholar
  21. 21.
    Jenkinson H. Retinoblastoma: diagnosis and management—the UK perspective. Arch Dis Child. 2015;100(11):1070–5.PubMedCrossRefGoogle Scholar
  22. 22.
    Abramson DH, Dunkel IJ, Brodie SE, Kim JW, Gobin YP. A phase I/II study of direct intra-arterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma: initial results. Ophthalmology. 2008;115(8):1398–404.PubMedCrossRefGoogle Scholar
  23. 23.
    Kaneko A, Suzuki S. Eye-preservation treatment of retinoblastoma with vitreous seeding. Jpn J Clin Oncol. 2003;33(12):601–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Suzuki S, Kaneko A. Management of intraocular retinoblastoma and ocular prognosis. Int J Clin Oncol. 2004;9(1):1–6.PubMedCrossRefGoogle Scholar
  25. 25.
    Shields CL, Jorge R, Say EAT, Magrath G, Alset A, Caywood E, et al. Unilateral retinoblastoma managed with intravenous chemotherapy versus intra-arterial chemotherapy. Outcomes based on the international classification of retinoblastoma. Asia Pac J Ophthalmol (Phila). 2016;5(2):97.CrossRefGoogle Scholar
  26. 26.
    Shields CL, Manjandavida FP, Lally SE, Pieretti G, Arepalli SA, Caywood EH, et al. Intra-arterial chemotherapy for retinoblastoma in 70 eyes: outcomes based on the international classification of retinoblastoma. Ophthalmology. 2014;121(7):1453–60.PubMedCrossRefGoogle Scholar
  27. 27.
    Tuncer S, Sencer S, Kebudi R, Tanyıldız B, Cebeci Z, Aydın K. Superselective intra-arterial chemotherapy in the primary management of advanced intra-ocular retinoblastoma: first 4-year experience from a single institution in Turkey. Acta Ophthalmol. 2016;94(7):e644–51.PubMedCrossRefGoogle Scholar
  28. 28.
    Shields CL, Alset AE, Say EAT, Caywood E, Jabbour P, Shields JA. Retinoblastoma control with primary intra-arterial chemotherapy: outcomes before and during the intravitreal chemotherapy era. J Pediatr Ophthalmol Strabismus. 2016;53(5):275–84.PubMedCrossRefGoogle Scholar
  29. 29.
    Say EAT, Iyer PG, Hasanreisoglu M, Lally SE, Jabbour P, Shields JA, et al. Secondary and tertiary intra-arterial chemotherapy for massive persistent or recurrent subretinal retinoblastoma seeds following previous chemotherapy exposure: long-term tumor control and globe salvage in 30 eyes. J AAPOS. 2016;20(4):337–42.PubMedCrossRefGoogle Scholar
  30. 30.
    Muen WJ, Kingston JE, Robertson F, Brew S, Sagoo MS, Reddy MA. Efficacy and complications of super-selective intra-ophthalmic artery melphalan for the treatment of refractory retinoblastoma. Ophthalmology. 2012;119(3):611–6.PubMedCrossRefGoogle Scholar
  31. 31.
    Gobin YP, Dunkel IJ, Marr BP, Brodie SE, Abramson DH. Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience. Arch Ophthalmol. 2011;129(6):732–7.PubMedCrossRefGoogle Scholar
  32. 32.
    Shields CL, Kaliki S, Al-Dahmash S, Rojanaporn D, Leahey A, Griffin G, et al. Management of advanced retinoblastoma with intravenous chemotherapy then intra-arterial chemotherapy as alternative to enucleation. Retina. 2013;33(10):2103.PubMedCrossRefGoogle Scholar
  33. 33.
    Abramson DH, Marr BP, Dunkel IJ, Brodie S, Zabor EC, Driscoll SJ, et al. Intra-arterial chemotherapy for retinoblastoma in eyes with vitreous and/or subretinal seeding: 2-year results. Br J Ophthalmol. 2012;96(4):499–502.PubMedCrossRefGoogle Scholar
  34. 34.
    Abramson DH, Marr BP, Francis JH, Dunkel IJ, Fabius AWM, Brodie SE, et al. Simultaneous bilateral ophthalmic artery chemosurgery for bilateral retinoblastoma (tandem therapy). PLoS One. 2016;11(6):e0156806.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Shields CL, Say EA, Pointdujour-Lim R, Cao C, Jabbour PM, Shields JA. Rescue intra-arterial chemotherapy following retinoblastoma recurrence after initial intra-arterial chemotherapy. J Fr Ophtalmol. 2015;38(6):542–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Leal-Leal CA, Asencio-López L, Higuera-Calleja J, Bernal-Moreno M, Bosch-Canto V, Chávez-Pacheco J, et al. Globe salvage with intra-arterial topotecan-melphalan chemotherapy in children with a single eye. Rev Invest Clin. 2016;68(3):137–42.PubMedGoogle Scholar
  37. 37.
    Chen M, Zhao J, Xia J, Liu Z, Jiang H, Shen G, et al. Intra-arterial chemotherapy as primary therapy for retinoblastoma in infants less than 3 months of age: a series of 10 case-studies. PLoS One. 2016;11(8):e0160873.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Magan T, Khoo CTL, Jabbour PM, Fuller DG, Shields CL. Intra-arterial chemotherapy for adult onset retinoblastoma in a 32-year-old man. J Pediatr Ophthalmol Strabismus. 2016;30(53):e43–6.Google Scholar
  39. 39.
    Rishi P, Sharma T, Koundanya V, Bansal N, Saravanan M, Ravikumar R, et al. Intra-arterial chemotherapy for retinoblastoma: first Indian report. Indian J Ophthalmol. 2015;63(4):331–4.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Shields CL, Ramasubramanian A, Rosenwasser R, Shields JA. Superselective catheterization of the ophthalmic artery for intra-arterial chemotherapy for retinoblastoma. Retina. 2009;29(8):1207–9.PubMedCrossRefGoogle Scholar
  41. 41.
    Michaels ST, Abruzzo TA, Augsburger JJ, Corrêa ZM, Lane A, Geller JI. Selective ophthalmic artery infusion chemotherapy for advanced intraocular retinoblastoma: CCHMC early experience. J Pediatr Hematol Oncol. 2016;38(1):65–9.PubMedCrossRefGoogle Scholar
  42. 42.
    Yannuzzi NA, Francis JH, Marr BP, Belinsky I, Dunkel IJ, Gobin YP, et al. Enucleation vs. ophthalmic artery chemosurgery for advanced intraocular retinoblastoma: a retrospective analysis. JAMA Ophthalmol. 2015;133(9):1062–6.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Simultaneous bilateral ophthalmic artery chemosurgery for bilateral retinoblastoma (tandem therapy). Accessed 8 Nov 2017.
  44. 44.
    Bertelli E, Leonini S, Galimberti D, Moretti S, Tinturini R, Hadjistilianou T, et al. Hemodynamic and anatomic variations require an adaptable approach during intra-arterial chemotherapy for intraocular retinoblastoma: alternative routes, strategies, and follow-up. Am J Neuroradiol. 2016;37(7):1289–95.PubMedCrossRefGoogle Scholar
  45. 45.
    Chawla B, Singh R. Recent advances and challenges in the management of retinoblastoma. Indian J Ophthalmol. 2017;65(2):133.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Inomata M, Kaneko A. Chemosensitivity profiles of primary and cultured human retinoblastoma cells in a human tumor clonogenic assay. Jpn J Cancer Res. 1987;78(8):858–68.PubMedGoogle Scholar
  47. 47.
    Munier FL, Gaillard M-C, Balmer A, Soliman S, Podilsky G, Moulin AP, et al. Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications. Br J Ophthalmol. 2012;96(8):1078–83.PubMedCrossRefGoogle Scholar
  48. 48.
    Munier FL, Soliman S, Moulin AP, Gaillard M-C, Balmer A, Beck-Popovic M. Profiling safety of intravitreal injections for retinoblastoma using an anti-reflux procedure and sterilisation of the needle track. Br J Ophthalmol. 2012;96(8):1084–7.PubMedCrossRefGoogle Scholar
  49. 49.
    Munier FL. Classification and management of seeds in retinoblastoma. Ellsworth Lecture Ghent August 24th 2013. Ophthalmic Genet. 2014;35(4):193–207.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Ghassemi F, Shields CL. Intravitreal melphalan for refractory or recurrent vitreous seeding from retinoblastoma. Arch Ophthalmol. 2012;130(10):1268–71.PubMedCrossRefGoogle Scholar
  51. 51.
    Francis JH, Abramson DH, Gaillard M-C, Marr BP, Beck-Popovic M, Munier FL. The classification of vitreous seeds in retinoblastoma and response to intravitreal melphalan. Ophthalmology. 2015;122(6):1173–9.PubMedCrossRefGoogle Scholar
  52. 52.
    Shields CL, Manjandavida FP, Arepalli S, Kaliki S, Lally SE, Shields JA. Intravitreal melphalan for persistent or recurrent retinoblastoma vitreous seeds: preliminary results. JAMA Ophthalmol. 2014;132(3):319–25.PubMedCrossRefGoogle Scholar
  53. 53.
    Kaneko A. Treatment of vitreous seed of retinoblastoma recurrent after chemoreduction using vitreous injection of melphalan. World Congress of Ophthalmology. 2006.Google Scholar
  54. 54.
    Brodie SE, Munier FL, Francis JH, Marr B, Gobin YP, Abramson DH. Persistence of retinal function after intravitreal melphalan injection for retinoblastoma. Doc Ophthalmol. 2013;126(1):79–84.PubMedCrossRefGoogle Scholar
  55. 55.
    Francis JH, Schaiquevich P, Buitrago E, Del Sole MJ, Zapata G, Croxatto JO, et al. Local and systemic toxicity of intravitreal melphalan for vitreous seeding in retinoblastoma: a preclinical and clinical study. Ophthalmology. 2014;121(9):1810–7.PubMedCrossRefGoogle Scholar
  56. 56.
    Smith SJ, Smith BD, Mohney BG. Ocular side effects following intravitreal injection therapy for retinoblastoma: a systematic review. Br J Ophthalmol. 2014;98(3):292–7.PubMedCrossRefGoogle Scholar
  57. 57.
    Ghassemi F, Shields CL, Ghadimi H, Khodabandeh A, Roohipoor R. Combined intravitreal melphalan and topotecan for refractory or recurrent vitreous seeding from retinoblastoma. JAMA Ophthalmol. 2014;132(8):936–41.PubMedCrossRefGoogle Scholar
  58. 58.
    Abramson DH, Schefler AC. Update on retinoblastoma. Retina. 2004;24(6):828–48.PubMedCrossRefGoogle Scholar
  59. 59.
    Mulvihill A, Budning A, Jay V, Vandenhoven C, Heon E, Gallie BL, et al. Ocular motility changes after subtenon carboplatin chemotherapy for retinoblastoma. Arch Ophthalmol. 2003;121(8):1120–4.PubMedCrossRefGoogle Scholar
  60. 60.
    Abramson DH, Frank CM, Dunkel IJ. A phase I/II study of subconjunctival carboplatin for intraocular retinoblastoma. Ophthalmology. 1999;106(10):1947–50.PubMedCrossRefGoogle Scholar
  61. 61.
    Shields CL, Shields JA. Diagnosis and management of retinoblastoma. Cancer Control. 2004;11(5):317–27.PubMedCrossRefGoogle Scholar
  62. 62.
    Manjandavida FP, Honavar SG, Reddy VAP, Khanna R. Management and outcome of retinoblastoma with vitreous seeds. Ophthalmology. 2014;121(2):517–24.PubMedCrossRefGoogle Scholar
  63. 63.
    Kang SJ, Durairaj C, Kompella UB, O’Brien JM, Liu K, Grossniklaus HE. Subconjunctival nanoparticle carboplatin in the treatment of transgenic murine retinoblastoma. Invest Ophthalmol Vis Sci. 2008;49(13):2017.Google Scholar
  64. 64.
    Kalita D, Shome D, Jain VG, Chadha K, Bellare JR. In vivo intraocular distribution and safety of periocular nanoparticle carboplatin for treatment of advanced retinoblastoma in humans. Am J Ophthalmol. 2014;157(5):1109–15.PubMedCrossRefGoogle Scholar
  65. 65.
    Shah PK, Kalpana N, Narendran V, Ramakrishnan M. Severe aseptic orbital cellulitis with subtenon carboplatin for intraocular retinoblastoma. Indian J Ophthalmol. 2011;59(1):49–51.PubMedPubMedCentralCrossRefGoogle Scholar
  66. 66.
    Schmack I, Hubbard GB, Kang SJ, Aaberg TM, Grossniklaus HE. Ischemic necrosis and atrophy of the optic nerve after periocular carboplatin injection for intraocular retinoblastoma. Am J Ophthalmol. 2006;142(2):310–5.PubMedCrossRefGoogle Scholar
  67. 67.
    Martin NE, Kim JW, Abramson DH. Fibrin sealant for retinoblastoma: where are we? J Ocul Pharmacol Ther. 2008;24(5):433–8.PubMedCrossRefGoogle Scholar
  68. 68.
    Chawla B, Jain A, Seth R, Azad R, Mohan VK, Pushker N, et al. Clinical outcome and regression patterns of retinoblastoma treated with systemic chemoreduction and focal therapy: a prospective study. Indian J Ophthalmol. 2016;64(7):524.PubMedPubMedCentralCrossRefGoogle Scholar
  69. 69.
    Shields JA, Parsons H, Shields CL, Giblin ME. The role of cryotherapy in the management of retinoblastoma. Am J Ophthalmol. 1989;108(3):260–4.PubMedCrossRefGoogle Scholar
  70. 70.
    Shields CL, Santos MCM, Diniz W, Gündüz K, Mercado G, Cater JR, et al. Thermotherapy for retinoblastoma. Arch Ophthalmol. 1999;117(7):885–93.PubMedCrossRefGoogle Scholar
  71. 71.
    Shields CL, Shields JA, Kiratli H, De PP. Treatment of retinoblastoma with indirect ophthalmoscope laser photocoagulation. J Pediatr Ophthalmol Strabismus. 1995;32(5):317–22.PubMedGoogle Scholar
  72. 72.
    Shields CL, Mashayekhi A, Cater J, Shelil A, Ness S, Meadows AT, et al. Macular retinoblastoma managed with chemoreduction: analysis of tumor control with or without adjuvant thermotherapy in 68 tumors. Arch Ophthalmol. 2005;123(6):765–73.PubMedCrossRefGoogle Scholar
  73. 73.
    Gombos DS, Kelly A, Coen PG, Kingston JE, Hungerford JL. Retinoblastoma treated with primary chemotherapy alone: the significance of tumour size, location, and age. Br J Ophthalmol. 2002;86(1):80–3.PubMedPubMedCentralCrossRefGoogle Scholar
  74. 74.
    Schefler AC, Cicciarelli N, Feuer W, Toledano S, Murray TG. Macular retinoblastoma: evaluation of tumor control, local complications, and visual outcomes for eyes treated with chemotherapy and repetitive foveal laser ablation. Ophthalmology. 2007;114(1):162–9.PubMedCrossRefGoogle Scholar
  75. 75.
    Shields CL, Mashayekhi A, Sun H, Uysal Y, Friere J, Komarnicky L, et al. Iodine 125 plaque radiotherapy as salvage treatment for retinoblastoma recurrence after chemoreduction in 84 tumors. Ophthalmology. 2006;113(11):2087–92.PubMedCrossRefGoogle Scholar
  76. 76.
    Schueler AO, Flühs D, Anastassiou G, Jurklies C, Sauerwein W, Bornfeld N. Beta-ray brachytherapy of retinoblastoma: feasibility of a new small-sized ruthenium-106 plaque. Ophthalmic Res. 2006;38(1):8–12.PubMedCrossRefGoogle Scholar
  77. 77.
    Abouzeid H, Moeckli R, Gaillard M-C, Beck-Popovic M, Pica A, Zografos L, et al. 106Ruthenium brachytherapy for retinoblastoma. Int J Radiat Oncol Biol Phys. 2008;71(3):821–8.PubMedCrossRefGoogle Scholar
  78. 78.
    Merchant TE, Gould CJ, Wilson MW, Hilton NE, Rodriguez-Galindo C, Haik BG. Episcleral plaque brachytherapy for retinoblastoma. Pediatr Blood Cancer. 2004;43(2):134–9.PubMedCrossRefGoogle Scholar
  79. 79.
    Shields CL, Shields JA, De Potter P, Minelli S, Hernandez C, Brady LW, et al. Plaque radiotherapy in the management of retinoblastoma: use as a primary and secondary treatment. Ophthalmology. 1993;100(2):216–24.PubMedCrossRefGoogle Scholar
  80. 80.
    Shields CL, Shields JA, Cater J, Othmane I, Singh AD, Micaily B. Plaque radiotherapy for retinoblastoma: long-term tumor control and treatment complications in 208 tumors. Ophthalmology. 2001;108(11):2116–21.PubMedCrossRefGoogle Scholar
  81. 81.
    American Brachytherapy Society—Ophthalmic Oncology Task Force. Electronic address:, ABS—OOTF Committee. The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. Brachytherapy. 2014;13(1):1–14.CrossRefGoogle Scholar
  82. 82.
    Eldebawy E, Parker W, Abdel Rahman W, Freeman CR. Dosimetric study of current treatment options for radiotherapy in retinoblastoma. Int J Radiat Oncol Biol Phys. 2012;82(3):e501–5.PubMedCrossRefGoogle Scholar
  83. 83.
    Eldebawy E, Patrocinio H, Evans M, Hashem R, Nelson S, Sidi R, et al. Stereotactic radiotherapy as an alternative to plaque brachytherapy in retinoblastoma. Pediatr Blood Cancer. 2010;55(6):1210–2.PubMedCrossRefGoogle Scholar
  84. 84.
    Sethi RV, Shih HA, Yeap BY, Mouw KW, Petersen R, Kim DY, et al. Second nonocular tumors among survivors of retinoblastoma treated with contemporary photon and proton radiotherapy. Cancer. 2014;120(1):126–33.PubMedCrossRefGoogle Scholar
  85. 85.
    Kaliki S, Srinivasan V, Gupta A, Mishra DK, Naik MN. Clinical features predictive of high-risk retinoblastoma in 403 Asian Indian patients: a case-control study. Ophthalmology. 2015;122(6):1165–72.PubMedCrossRefGoogle Scholar
  86. 86.
    Mudhar S, Brundler MA, Luthert P. Standards and datasets for reporting cancers. Dataset for ocular retinoblastoma histopathology reports. Rep R Coll Pathol. 2010.Google Scholar
  87. 87.
    Messmer EP, Heinrich T, Höpping W, de Sutter E, Havers W, Sauerwein W. Risk factors for metastases in patients with retinoblastoma. Ophthalmology. 1991;98(2):136–41.PubMedCrossRefGoogle Scholar
  88. 88.
    Shields CL, Shields JA, Baez KA, Cater J, De Potter PV. Choroidal invasion of retinoblastoma: metastatic potential and clinical risk factors. Br J Ophthalmol. 1993;77(9):544–8.PubMedPubMedCentralCrossRefGoogle Scholar
  89. 89.
    Shields CL, Shields JA, Baez K, Cater JR, De Potter P. Optic nerve invasion of retinoblastoma. Metastatic potential and clinical risk factors. Cancer. 1994;73(3):692–8.PubMedCrossRefGoogle Scholar
  90. 90.
    Eagle RC Jr. High-risk features and tumor differentiation in retinoblastoma: a retrospective histopathologic study. Arch Pathol Lab Med. 2009;133(8):1203–9.PubMedGoogle Scholar
  91. 91.
    Uusitalo MS, Van Quill KR, Scott IU, Matthay KK, Murray TG, O’brien JM. Evaluation of chemoprophylaxis in patients with unilateral retinoblastoma with high-risk features on histopathologic examination. Arch Ophthalmol. 2001;119(1):41–8.PubMedGoogle Scholar
  92. 92.
    Honavar SG, Singh AD, Shields CL, Meadows AT, Demirci H, Cater J, et al. Postenucleation adjuvant therapy in high-risk retinoblastoma. Arch Ophthalmol. 2002;120(7):923–31.PubMedCrossRefGoogle Scholar
  93. 93.
    Chantada GL, Casco F, Fandiño AC, Galli S, Manzitti J, Scopinaro M, et al. Outcome of patients with retinoblastoma and postlaminar optic nerve invasion. Ophthalmology. 2007;114(11):2083–9.PubMedCrossRefGoogle Scholar
  94. 94.
    Honavar SG. Orbital retinoblastoma. In: Clinical ophthalmic oncology [Internet]. Berlin: Springer; 2015. p. 185–94. Accessed 18 Nov 2017.Google Scholar
  95. 95.
    Chawla B, Hasan F, Azad R, Seth R, Upadhyay AD, Pathy S, et al. Clinical presentation and survival of retinoblastoma in Indian children. Br J Ophthalmol. 2016;100(2):172–8.PubMedCrossRefGoogle Scholar
  96. 96.
    Ali MJ, Honavar SG, Reddy VAP. Orbital retinoblastoma: present status and future challenges—a review. Saudi J Ophthalmol. 2011;25(2):159–67.PubMedCrossRefGoogle Scholar
  97. 97.
    Badhu B, Sah SP, Thakur SK, Dulal S, Kumar S, Sood A, et al. Clinical presentation of retinoblastoma in Eastern Nepal. Clin Exp Ophthalmol. 2005;33(4):386–9.PubMedCrossRefGoogle Scholar
  98. 98.
    Honavar SG, Manjandavida FP, Reddy VAP. Orbital retinoblastoma: an update. Indian J Ophthalmol. 2017;65(6):435–42.PubMedPubMedCentralCrossRefGoogle Scholar
  99. 99.
    Gündüz K, Müftüoglu O, Günalp I, Unal E, Taçyildiz N. Metastatic retinoblastoma clinical features, treatment, and prognosis. Ophthalmology. 2006;113(9):1558–66.PubMedCrossRefGoogle Scholar
  100. 100.
    Moll AC, Hoekstra OS, Imhof SM, Comans EF, Schouten-van Meeteren AYN, van der Valk P, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography (PET) to detect vital retinoblastoma in the eye: preliminary experience. Ophthalmic Genet. 2004;25(1):31–5.PubMedCrossRefGoogle Scholar
  101. 101.
    Kiratli PO, Kiratli H, Ercan MT. Visualization of orbital retinoblastoma with technetium-99m (V) dimercaptosuccinic acid. Ann Nucl Med. 1998;12(3):157–9.PubMedCrossRefGoogle Scholar
  102. 102.
    Antoneli CBG, Steinhorst F, de Cássia Braga Ribeiro K, PERS N, MMM C, Arias V, et al. Extraocular retinoblastoma: a 13-year experience. Cancer. 2003;98(6):1292–8.PubMedCrossRefGoogle Scholar
  103. 103.
    Chantada G, Fandiño A, Casak S, Manzitti J, Raslawski E, Schvartzman E. Treatment of overt extraocular retinoblastoma. Med Pediatr Oncol. 2003;40(3):158–61.PubMedCrossRefGoogle Scholar
  104. 104.
    Chantada GL, Guitter MR, Fandiño AC, Raslawski EC, de Davila MTG, Vaiani E, et al. Treatment results in patients with retinoblastoma and invasion to the cut end of the optic nerve. Pediatr Blood Cancer. 2009;52(2):218–22.PubMedCrossRefGoogle Scholar
  105. 105.
    Finger PT, Harbour JW, Karcioglu ZA. Risk factors for metastasis in retinoblastoma. Surv Ophthalmol. 2002;47(1):1–16.PubMedCrossRefGoogle Scholar
  106. 106.
    Singh AD, Shields CL, Shields JA. Prognostic factors in retinoblastoma. J Pediatr Ophthalmol Strabismus. 2000;37(3):134–41. quiz 168-169.PubMedGoogle Scholar
  107. 107.
    Chawla B, Hasan F, Seth R, Pathy S, Pattebahadur R, Sharma S, et al. Multimodal therapy for stage III retinoblastoma (international retinoblastoma staging system): a prospective comparative study. Ophthalmology. 2016;123(9):1933–9.PubMedCrossRefGoogle Scholar
  108. 108.
    Ali MJ, Honavar SG, Reddy VA. Distant metastatic retinoblastoma without central nervous system involvement. Indian J Ophthalmol. 2013;61(7):357–9.PubMedPubMedCentralCrossRefGoogle Scholar
  109. 109.
    Dunkel IJ, Khakoo Y, Kernan NA, Gershon T, Gilheeney S, Lyden DC, et al. Intensive multimodality therapy for patients with stage 4a metastatic retinoblastoma. Pediatr Blood Cancer. 2010;55(1):55–9.PubMedGoogle Scholar
  110. 110.
    Matsubara H, Makimoto A, Higa T, Kawamoto H, Sakiyama S, Hosono A, et al. A multidisciplinary treatment strategy that includes high-dose chemotherapy for metastatic retinoblastoma without CNS involvement. Bone Marrow Transplant. 2005;35(8):763–6.PubMedCrossRefGoogle Scholar
  111. 111.
    Malik M, Prabhakar R, Sharma DN, Rath GK. Retinoblastoma with cerebrospinal fluid metastasis treated with orbital and craniospinal irradiation using IMRT. Technol Cancer Res Treat. 2006;5(5):497–501.PubMedCrossRefGoogle Scholar
  112. 112.
    Dunkel IJ, Chan HSL, Jubran R, Chantada GL, Goldman S, Chintagumpala M, et al. High-dose chemotherapy with autologous hematopoietic stem cell rescue for stage 4B retinoblastoma. Pediatr Blood Cancer. 2010;55(1):149–52.PubMedGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Shweta Gupta
    • 1
  • Swathi Kaliki
    • 1
  1. 1.The Operation Eyesight Universal Institute for Eye CancerL V Prasad Eye InstituteHyderabadIndia

Personalised recommendations